With respect to programmed death-ligand 1 (PD-L1), the target axis molecule of immune checkpoint inhibitor (ICI), TAMs have been reported to promote the expression of PD-L1 in pancreatic cancer [22]. This evidence concerns the gene CD274 and pancreatic neoplasm.